Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Notes Payables (2024 - 2025)

Historic Notes Payables for HCW Biologics (HCWB) over the last 2 years, with Q3 2025 value amounting to $6.8 million.

  • HCW Biologics' Notes Payables rose 736.41% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year increase of 736.41%. This contributed to the annual value of $6.3 million for FY2024, which is N/A changed from last year.
  • Per HCW Biologics' latest filing, its Notes Payables stood at $6.8 million for Q3 2025, which was up 736.41% from $6.4 million recorded in Q2 2025.
  • Over the past 5 years, HCW Biologics' Notes Payables peaked at $6.8 million during Q3 2025, and registered a low of $6.2 million during Q1 2025.